Jacek P Olczak

This inventor holds 12 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Oncoarendi Therapeutics S.a., Oncoarendi Therapeutics Sp. Z O.o., Instytut Biochemii I Biofizyki Polskiej Akademii Nauk. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jacek P Olczak. Retrieved from https://idiyas.com/inventor/jacek-p-olczak

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 2)

% Patents Active = 91.7

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 8.7

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Łodź, PL (2016)
Łódź, PL (2018 - 2019)
Lodz, PL (2017 - 2024)

Company Filing History:

8 out of 8

Oncoarendi Therapeutics S.a.

patents

2 out of 2

Oncoarendi Therapeutics Sp. Z O.o.

patents

1 out of 3

Instytut Biochemii I Biofizyki Polskiej Akademii Nauk

patents

4. 1 out of 1

Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej W Warszawie

The Institute for Pharmaceutical Discovery, LLC

patents

where one patent can have more than one assignee

Years Active: 2016-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12053451 - Arginase inhibitors and their therapeutic applications (2024-08-06),

2. 11638707 - Substituted amino triazoles useful as chitinase inhibitors (2023-05-02),

3. 10912755 - Arginase inhibitors and their therapeutic applications (2021-02-09),

4. 10851099 - Dipeptide piperidine derivatives (2020-12-01),

5. 10538508 - Substituted amino triazoles useful as human chitinase inhibitors (2020-01-21),

6. 10391077 - Arginase inhibitors and their therapeutic applications (2019-08-27),

7. 10329310 - Arginase inhibitors and their therapeutic applications (2019-06-25),

8. 10214531 - Substituted amino triazoles, and methods using same (2019-02-26),

9. 10208020 - Substituted amino triazoles useful as human chitinase inhibitors (2019-02-19),

10. 9944624 - Substituted amino triazoles useful as human chitinase inhibitors (2018-04-17),

11. 9611514 - Method for selection of hDIS3 PIN domain inhibitors and use of hDIS3 PIN domain inhibitors for cancer treatment (2017-04-04),

12. 9440953 - Substituted amino triazoles useful as acidic mammalian chitinase inhibitors (2016-09-13),

Title: Jacek P Olczak: Innovator in Therapeutic Applications

Introduction

Jacek P Olczak is a prominent inventor based in Łódź, Poland, known for his significant contributions to the field of therapeutic compounds. With a total of 12 patents to his name, he has made remarkable strides in developing innovative solutions for various medical conditions.

Latest Patents

Among his latest patents, Olczak has developed small molecule therapeutic compounds that act as potent inhibitors of arginase 1 and arginase 2 activity. These compounds are crucial for creating pharmaceutical compositions aimed at treating or preventing diseases associated with arginase activity. Another notable patent involves substituted amino triazoles, which serve as inhibitors of acidic mammalian chitinase and chitotriosidase. These compounds are designed to treat asthma reactions caused by allergens, as well as a range of inflammatory, autoimmune, dental, neurologic, metabolic, liver diseases, polycystic ovary syndrome, endometriosis, and cancer.

Career Highlights

Olczak has worked with Oncoarendi Therapeutics S.A. and Oncoarendi Therapeutics Sp. z o.o., where he has played a vital role in advancing therapeutic research and development. His work has been instrumental in pushing the boundaries of medical science and improving patient outcomes.

Collaborations

Throughout his career, Jacek P Olczak has collaborated with notable professionals, including Adam A Golebiowski and Bartlomiej Borek. These partnerships have contributed to the success of his innovative projects and patents.

Conclusion

Jacek P Olczak stands out as a key figure in the field of therapeutic innovations, with a strong portfolio of patents that address critical health issues. His work continues to impact the medical community positively, paving the way for future advancements in treatment options.

Profile summary based on public USPTO records.